APABETALONE, also known as RVX-208, is a pharmaceutical substance that has been developed for the treatment of various cardiovascular conditions. Its chemical name is 4-(1-(4-fluorophenyl)-5-(3-(4-fluorophenyl)-1H-pyrazol-1-yl)-, 2H-thieno(3,2-b)pyridin-7-yl)butanoic acid.
The CAS number for APABETALONE is 1044870-39-4. It works by modulating certain genes involved in lipid metabolism, resulting in the increase of high-density lipoprotein (HDL) cholesterol levels.
APABETALONE has shown potential in clinical trials for its ability to reduce atherosclerosis and improve cardiovascular outcomes. It has also demonstrated anti-inflammatory effects and has been investigated as a potential treatment for other inflammatory disorders.
Further research and clinical trials are necessary to fully understand the safety and efficacy of APABETALONE in different patient populations and indications.
